Sanofi-Aventis and UK gene-therapy developer Oxford BioMedica, have announced a joint-collaboration agreement to develop and market the pipeline cancer treatment TroVax.
Under terms of the deal, Sanofi-Aventis will pay Oxford BioMedica, the owner of TroVax, up to $690 million if all development and registration targets are met for certain uses, the companies said. Additional payments will be made to Oxford BioMedica if regulatory milestones are achieved in other cancer types. Oxford BioMedica will receive an initial payment of $39 million and further payments of $25 million as targets are reached
TroVax is Oxford BioMedica’s main cancer immunotherapy. Early research suggests TroVax has potential for applications in a wide range of solid tumors, including renal, colorectal, lung, breast and prostate cancer. A Phase III trial in renal cancer is ongoing.
Both companies will co-fund the renal cancer study, while Sanofi-Aventis will fund all future research, development, regulatory and marketing.
Oxford BioMedica has an option to develop TroVax for other cancer types in exchange for enhanced financial returns under terms where Sanofi-Aventis would keep all commercial rights.
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.